Thyroideum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dried mammalian thyroid preparation standardized to a fixed levothyroxine-to-liothyronine ratio and total iodine content. The product is not a synthetic single-entity drug but a complex biological derivative containing thyroglobulin-derived peptides, residual tissue matrix, and the natural thyroid hormone pair. The compendial name functions as the primary model descriptor; no unified manufacturer model code exists across pharmacopoeias, although individual marketing authorization holders assign batch-specific grade codes for veterinary use. The material is controlled under USP Thyroid and Ph. Eur. 0339 monographs when the regional submission references those standards. The veterinary grade designation adds supplementary release criteria for endotoxins, bioburden, and particulate matter where the same powder is declared for injection or solution compounding. The dried powder is supplied with a specified iodine content in the range of 0.17%–0.23% on a dried basis, a levothyroxine-to-liothyronine ratio of approximately 4:1, and a loss-on-drying limit of not more than 6.0% where the compendial limit is applied. The multi-dosage-form declaration requires the formulator to assess whether the received powder meets the tighter injectable-grade endotoxin threshold and particulate limits before use in parenteral products. For tablets, capsules, and granules, the same API lot may be used if it passes solid-dosage-specific sieve fraction and flowability checks. The API is intended for incorporation into prescription veterinary medicines for thyroid hormone replacement in species such as dogs and horses; the marketing authorization holder must confirm species-specific dosing, target animal safety, and withdrawal periods where food-producing species are involved.

What Pharmacopoeial Specifications Govern Thyroideum Veterinary Grade API?

Compendial control relies on a matrix of chemical, physical, and microbiological tests. The primary chemical marker is total iodine content because it correlates with thyroid hormone content after complete digestion. The assay for levothyroxine and liothyronine is performed by high-performance liquid chromatography with ultraviolet detection. The ratio of T4 to T3 is a batch consistency marker; natural thyroid preparations show a consistent ratio of approximately 4:1. Residual moisture is measured by loss on drying. Bulk density and tapped density are measured for solid oral form selection. Injectable use requires bacterial endotoxin testing and particulate matter evaluation according to the relevant parenteral monograph. Where a compendial value is not fixed, the entry is marked as batch-specific because published data for that exact veterinary-grade configuration is limited.

Bulk density and tapped density are measured under Ph. Eur. 2.9.34 because the flowability of natural thyroid powder is sensitive to particle morphology. Milled powders with high aspect ratio particles show lower bulk density and require forced-flow feeders on capsule and tablet presses. Spherical agglomerates produced by wet granulation improve flow but may delay dissolution unless a superdisintegrant such as sodium starch glycolate is included at 2.0%–4.0% w/w. The choice of granulation binder also affects hormone stability; povidone-based binders at 5.0% w/w are generally compatible, while certain starch binders with reducing sugar content may promote Maillard degradation of the peptide fraction. These incompatibility boundaries are established by forced-degradation studies under ICH Q1A and VICH GL3 conditions.

When Thyroid Powder Transitions from Dry Blend to Sterile Injectable Solution

Injection and solution compounding impose constraints not present in solid oral forms. The dry thyroid powder is only partially soluble in aqueous media because thyroglobulin-derived material and residual tissue matrix remain as suspended particles. Preparation of a true solution for injection therefore requires dissolution of the active hormone fraction followed by clarification through a 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride membrane filter. If the starting powder has not been pre-sieved through a 0.500 mm screen, filter loading accelerates and throughput drops. On production-scale lines using cartridge filtration, the maximum filter area should be selected from small-scale filterability data rather than a fixed flux value; published data for this specific configuration is limited. The injectable grade also requires bacterial endotoxin control, typically by closed processing, use of low-endotoxin starting tissue, and terminal sterile filtration where the formulation permits. Heat depyrogenation is not suitable for a proteinaceous glandular product because prolonged exposure above 40°C may accelerate hormone degradation and protein denaturation. The veterinary grade API for powders and granules does not automatically meet injectable-grade bioburden; the formulator must verify batch-specific data before declaring dual-use status. For solutions intended for oral or topical veterinary use, the same API can be dispersed in a buffered vehicle at pH 8.0–9.5, but a solubilizer such as polysorbate 80 may be required to wet the hydrophobic tissue matrix. The use of ultrasonication is limited to short cycles because cavitation can generate local hot spots and free radicals that degrade levothyroxine.

For injectable solutions, the final formulation is typically filled under nitrogen into Type I glass vials sealed with chlorobutyl elastomeric closures. The headspace oxygen limit is set below 5.0% to reduce oxidative degradation of liothyronine, which is more susceptible than levothyroxine. Terminal sterilization using moist heat at 121°C for 15 minutes is generally not applicable to natural thyroid solutions because of proteinaceous flocculation; therefore, aseptic processing with 0.22 µm sterilizing filtration is the accepted route when a solution is requested. Lyophilized powders for reconstitution can be prepared from the filtered solution by freezing at −40°C and primary drying at −20°C under 0.2 mbar, but published cycle data for this specific veterinary-grade natural product is limited and must be developed during process validation.

Particle Size, Hormone Ratio, and Residual Moisture Limits Across Solid Oral Forms

The same API lot is not equally suitable for all solid oral forms without tailoring. For tablet manufacture, direct compression demands a flowable powder with a Carr index below 20%; if compressibility index exceeds 25%, wet granulation with a low-shear planetary mixer or high-shear granulator is used. The natural thyroid powder is cohesive because of residual lipids and proteinaceous material; it is often pre-blended with microcrystalline cellulose or lactose monohydrate before tablet compression. For capsule filling, the powder is dry-mixed and filled on a dosator or tamping-pin machine; segregation is minimized when the API particle size is controlled at D90 ≤ 150 µm and the excipient particle size is matched within 20% of the API median diameter. For powders and granules used as premix, the primary control is blend uniformity rather than tablet compactability; the coefficient of variation for levothyroxine content across 10 stratified samples should be ≤ 5.0% as per standard blend uniformity guidance. Residual moisture above 6.0% increases the risk of mold growth in non-sterile oral powders; pre-drying at 40°C ± 2°C under vacuum is used before final packaging when relative humidity during processing exceeds 60% RH. The API is pre-sieved through a 0.500 mm screen to remove agglomerates before blending. For premix applications, the API is distributed on a lactose or calcium carbonate carrier at a dilution ratio between 1:10 and 1:100 w/w to achieve uniform mixing in feed. The exact ratio is determined by the target dose per kilogram of body weight and the final premix inclusion rate.

Batch-to-batch variance in natural thyroid API is higher than synthetic salts because the starting tissue iodine content varies with animal species, diet, and season. The manufacturer normalizes the raw glandular material by blending lots to hit the total iodine range and the T4/T3 ratio. On a twin-screw wet granulation line with an L/D ratio of 25:1, the granulation endpoint shifts if the API moisture content varies by more than 1.0%; therefore, in-process loss-on-drying checks are performed every 30 minutes during the first production campaign. For direct compression on a rotary tablet press with a turret speed up to 60 rpm, the powder blend requires an adequate bulk density to maintain die fill consistency. Published data for this specific natural thyroid configuration is limited, so these limits are typically established during process validation rather than taken from public monographs.

Differences from synthetic levothyroxine sodium and liothyronine sodium extend beyond active substance composition. Synthetic levothyroxine sodium is a single chemical entity with defined stoichiometry and high aqueous solubility at alkaline pH; the natural thyroid API contains thyroglobulin-derived peptides and residual tissue matrix that modify dissolution in solid oral forms and reduce solubility in neutral aqueous vehicles. The natural product’s hormone ratio is approximately 4:1 T4:T3, whereas synthetic formulations can be adjusted to any ratio. This fixed ratio is a regulatory and clinical distinction: it prevents independent titration of levothyroxine and liothyronine in veterinary patients. The natural API also carries a different allergen and transmissible spongiform encephalopathy risk profile because it is gland-derived; veterinary grade shipments must include a TSE/BSE declaration under Ph. Eur. 5.2.8 or equivalent regional guidance. Synthetic levothyroxine sodium has no such requirement. Table 2 lists these distinctions.

The fixed natural T4/T3 ratio has practical consequences in veterinary compounding. A synthetic combination can be prepared at ratios of 4:1, 10:1, or any prescribed proportion, while Thyroideum veterinary grade API fixes the proportion at the glandular natural value. This affects dose calculation for species that metabolize T4 and T3 differently. However, the natural matrix may provide thyroglobulin peptides that are absent in synthetic salts; the clinical relevance of those peptides is not established in veterinary pharmacotherapy, and published controlled data is limited. The presence of residual tissue matrix also affects analytical testing: synthetic APIs are assayed as single peaks, while the natural API requires a multi-analyte method with baseline separation of levothyroxine, liothyronine, diiodotyrosine, and monoiodotyrosine under gradient HPLC conditions. The natural API may produce a more variable dissolution profile in immediate-release tablets unless the formulation includes a disintegrant such as crospovidone and a wetting agent such as sodium lauryl sulfate. Synthetic levothyroxine sodium tablets generally show narrower dissolution variability because of the single defined salt.

Stability boundaries for multi-dosage-form thyroid API are governed by moisture, temperature, and oxidation. The powder should be stored in tight containers at 2–8°C, protected from light and oxygen. Open storage at ambient conditions above 25°C and 60% RH accelerates moisture uptake and can cause discoloration, caking, and loss of levothyroxine content. The API is incompatible with strong oxidizing agents, including peroxides and hypochlorites, which degrade the phenolic hormone structure. Avoid combination with amine-based high-reactivity excipients in dry blends unless compatibility studies demonstrate no Maillard-type degradation over the intended shelf life. The product should not be exposed to ethylene oxide sterilization because residual ethylene oxide and its reaction products can alter hormone stability. When the API is used for solutions, the vehicle pH is maintained between 8.0 and 9.5 using sodium hydroxide or trometamol; acidic conditions below pH 6.0 reduce levothyroxine solubility and may precipitate the active fraction. Published data for specific veterinary solution stability is limited, therefore real-time and accelerated stability studies should follow VICH GL3 and VICH GL5 protocols. The API should be re-tested every 12 months when stored unopened at 2–8°C; opened containers should be purged with nitrogen and re-sealed immediately to limit oxidative degradation.